Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alector, Inc.
  6. Summary
    ALEC   US0144421072

ALECTOR, INC.

(ALEC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
19.41(c) 19.62(c) 21.19(c) 22.48(c) 22.43(c) Last
390 324 414 046 610 400 930 083 1 789 874 Volume
+0.15% +1.08% +8.00% +6.09% -0.22% Change
More quotes
Financials (USD)
Sales 2021 32,1 M - -
Net income 2021 -228 M - -
Net cash position 2021 302 M - -
P/E ratio 2021 -7,96x
Yield 2021 -
Sales 2022 45,7 M - -
Net income 2022 -247 M - -
Net cash position 2022 324 M - -
P/E ratio 2022 -7,86x
Yield 2022 -
Capitalization 1 789 M 1 789 M -
EV / Sales 2021 46,3x
EV / Sales 2022 32,0x
Nbr of Employees 181
Free-Float 86,8%
More Financials
Company
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy... 
Sector
Biotechnology & Medical Research
Calendar
06/17 | 11:00amShareholder meeting
More about the company
Ratings of Alector, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ALECTOR, INC.
06/11ALECTOR  : Virtual Key Opinion Leader Event on Frontotemporal Dementia
PU
06/03Alector to Present at Upcoming Virtual Healthcare Conferences
GL
06/02CENTOGENE N  : Launches Observational Study on Genetic Mutations in Patients Wit..
MT
05/26Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia o..
GL
05/06ALECTOR  : to Present at the BofA Securities 2021 Virtual Health Care Conference
AQ
05/05ALECTOR : Q1 Earnings Snapshot
AQ
05/05ALECTOR  : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/05ALECTOR, INC.  : Results of Operations and Financial Condition, Financial Statem..
AQ
05/05Alector Reports 2021 First Quarter Financial Results and Provides Business Up..
GL
04/19ALECTOR  : Morgan Stanley Adjusts Price Target on Alector to $33 From $31, Maint..
MT
03/26ALECTOR, INC.  : Change in Directors or Principal Officers, Financial Statements..
AQ
03/26ALECTOR  : to Present at Stifel's 3rd Annual CNS Day
AQ
03/25ALECTOR  : to Present at Stifel's 3rd Annual CNS Day
AQ
03/05ALECTOR, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
03/04Alector to Present at the Barclays Global Healthcare Conference
GL
More news
News in other languages on ALECTOR, INC.
06/07AKTIEN IM FOKUS : Alzheimermittel hilft Biogen auf Rekordhoch - Morphosys fest
More news
Analyst Recommendations on ALECTOR, INC.
More recommendations
Chart ALECTOR, INC.
Duration : Period :
Alector, Inc. Technical Analysis Chart | ALEC | US0144421072 | MarketScreener
Technical analysis trends ALECTOR, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 32,00 $
Last Close Price 22,43 $
Spread / Highest target 82,8%
Spread / Average Target 42,7%
Spread / Lowest Target 24,8%
EPS Revisions
Managers and Directors
NameTitle
Arnon Rosenthal Chief Executive Officer & Director
Shehnaaz Suliman President & Chief Operating Officer
Calvin Yu Vice President-Finance
Tillman U. Gerngross Chairman
Robert Paul Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALECTOR, INC.48.25%1 793
GILEAD SCIENCES, INC.15.57%85 397
WUXI APPTEC CO., LTD.21.14%65 765
REGENERON PHARMACEUTICALS8.38%54 626
BIONTECH SE150.06%52 693
VERTEX PHARMACEUTICALS-20.67%48 918